The CD11b+CD11c+ DC subset has earlier been reported to play a role in generating tolerogenic and regulatory responses against chronic inflammation and hence is exploited to treat autoimmune diseases (Li et al., 2008). This evidence concerns the gene ITGAX and autoimmune disease.